Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin

被引:29
作者
Schmitz, FJ
Petridou, J
Jagusch, H
Astfalk, N
Scheuring, S
Schwarz, S [1 ]
机构
[1] Bundesforsch Anstalt Landwirtschaft, Inst Tierzucht & Tierverhalten, D-29223 Celle, Germany
[2] Univ Dusseldorf, Inst Med Mikrobiol & Virol, D-40225 Dusseldorf, Germany
关键词
D O I
10.1093/jac/49.4.611
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to investigate whether a Staphylococcus aureus strain that carried an inducibly expressed erm(A) gene might exhibit resistance to the non-inducers telithromycin, ABT-773, clindamycin, quinupristin, dalfopristin or the combination quinupristin-dalfopristin after incubation in the presence of inhibitory concentrations of any of these compounds. Whenever resistant mutants were obtained, these were investigated for the molecular basis of the altered resistance phenotype. Resistant mutants were not selected with dalfopristin or quinupristin-dalfopristin, but were obtained with the other four agents. Irrespective of which drug was used for selection, all mutants were cross-resistant to clindamycin, quinupristin, telithromycin and ABT-773, and exhibited structural alterations in the erm(A) translational attenuator. The structural alterations observed included deletions of 14, 83, 121, 131, 147 or 157 bp, three different tandem duplications of 23, 25 or 26 bp, two different types of point mutation, as well as the insertion of IS256. All these alterations either completely prevented the formation of mRNA secondary structures in the erm(A) regulatory region or favoured the formation of those mRNA secondary structures that allowed translation of the erm(A) transcripts. Deletions, which were observed in almost two-thirds of the mutants, might be explained by illegitimate recombination between different parts of the erm(A) regulatory region.
引用
收藏
页码:611 / 617
页数:7
相关论文
共 31 条
[1]   The in vitro activity of ABT773, a new ketolide antimicrobial agent [J].
Andrews, JM ;
Weller, TMA ;
Ashby, JP ;
Walker, RM ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) :1017-1022
[2]   Ketolides lack inducibility properties of MLSB resistance phenotype [J].
Bonnefoy, A ;
Girard, AM ;
Agouridas, C ;
Chantot, JF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :85-90
[3]   In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus [J].
Boos, M ;
Mayer, S ;
Fischer, A ;
Köhrer, K ;
Scheuring, S ;
Heisig, P ;
Verhoef, J ;
Fluit, AC ;
Schmitz, FJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :938-942
[4]  
Bryskier A, 1997, INFEC DIS T, V21, P39
[5]   MOLECULAR ANALYSIS OF A GENTAMICIN RESISTANCE TRANSPOSON-LIKE ELEMENT ON PLASMIDS ISOLATED FROM NORTH-AMERICAN STAPHYLOCOCCUS-AUREUS STRAINS [J].
BYRNE, ME ;
GILLESPIE, MT ;
SKURRAY, RA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (11) :2106-2113
[6]   Host range of the ermF rRNA methylase gene in bacteria of human and animal origin [J].
Chung, WSO ;
Werckenthin, C ;
Schwarz, S ;
Roberts, MC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :5-14
[7]   TRANSLATIONAL ATTENUATION - THE REGULATION OF BACTERIAL-RESISTANCE TO THE MACROLIDE-LINCOSAMIDE-STREPTOGRAMIN-B ANTIBIOTICS [J].
DUBNAU, D .
CRC CRITICAL REVIEWS IN BIOCHEMISTRY, 1984, 16 (02) :103-132
[8]   MULTIPLE COPIES OF IS256 IN STAPHYLOCOCCI [J].
DYKE, KGH ;
AUBERT, S ;
ELSOLH, N .
PLASMID, 1992, 28 (03) :235-246
[9]   Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study [J].
Fluit, AC ;
Wielders, CLC ;
Verhoef, J ;
Schmitz, FJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (10) :3727-3732
[10]   Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against Gram-positive cocci of known erythromycin susceptibility status [J].
Hamilton-Miller, JMT ;
Shah, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (06) :649-653